Recent Updates
Recently added Catalysts
CGC

CANOPY GROWTH REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS Business transformation continues to gain traction Improved commercial and operational execution drives record net revenue of $153 million, up 23% vs Q3 2

Key Takeaway: CANOPY GROWTH REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS Business transformation continues to gain traction Improved commercial and operational execution drives record net revenue of $153 million, up 23% vs Q3 2020 Q3 2021 Canadian recreational market share increased

Full Press Release Details

CANOPY GROWTH REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS
Business transformation continues to gain traction
Improved commercial and operational execution drives record net revenue of $153 million, up 23% vs Q3 2020
Q3 2021 Canadian recreational market share increased by 30bps vs Q2 2021 based on our proprietary market share tracker
Provides medium-term financial targets, including expectations to achieve profitability during the second half of FY 2022, while continuing to invest behind consumer insights, R&D and the U.S. market
With renewed sense of optimism, Canopy further advanced the U.S. growth strategy ahead of potential cannabis reform
SMITHS FALLS, ON - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) today announces its financial results for the third quarter fiscal 2021 ended December 31, 2020. All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated.
Third Quarter Fiscal 2021 Financial Summary
Net revenue Gross margin percentage Adjusted gross margin percentage 1 Net loss Adjusted EBITDA 2 Free cash flow 3
Reported $152.5 16% 26% $(829.3) $(68.4) $(135.4)
vs. Q3 2020 23% (1,500) bps (500) bps (656%) 29% 62%
1 Adjusted gross margin percentage is a non-GAAP measure, and for Q3 2021 excludes restructuring costs included in cost of goods sold of $15.6 million.
2 Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
3 Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
"We delivered another quarter of record net revenue, with growth across all our businesses, led by improved commercial and supply chain execution," said David Klein, CEO. "We are building a track record of winning in our core markets, while also accelerating our U.S. growth strategy with the momentum building behind the promising cannabis reform in the U.S."
"We are executing against our cost savings program, with several initiatives already completed and more underway to build a leaner and more agile business," added Mike Lee, CFO. "These cost savings, along with our top-line growth and continued cost discipline, puts Canopy firmly on a path to achieve profitability during Fiscal 2022, with further improvement anticipated beyond."
Medium-Term Financial Milestones
With our new strategy in place, our organizational changes complete, and our operational cost savings program now underway, the Company is in position to establish the following medium-term financial targets:
Key drivers underpinning the Company's financial targets include:
Third Quarter Fiscal 2021 Corporate Financial Highlights
Business & Operational Highlights
Third Quarter Fiscal 2021 Financial and Operational Review
(in millions of Canadian dollars, unaudited) Q3 2021 Q3 2020 vs. Q3 2020
Canadian recreational net revenue
- Business to business 1 $43.1 $43.0 NM
- Business to consumer $20.2 $15.2 33%
$63.3 $58.2 9%
Canadian medical net revenue 2 $14.0 $13.5 4%
International medical revenue $21.5 $18.7 15%
$35.5 $32.2 10%
Cannabis net revenue $98.8 $90.4 9%
All other revenue $53.7 $33.4 61%
Net revenue $152.5 $123.8 23%
1 Reflects excise taxes of $16.0 million and other revenue adjustments of $3.8 million for Q3 2021 (Q3 2020 - $10.5 million and $5.3 million, respectively).
2 Reflects excise taxes of $1.4 million in Q3 2021 (Q3 2020 - $1.3 million).
(in millions of Canadian dollars, unaudited) Q3 2021 Q3 2020 vs. Q3 2020
Canadian recreational net revenue
- Dry bud 1 $66.2 $69.3 (4%)
- Oils and softgels 1 $7.3 $4.7 55%
- Cannabis 2.0 products 2 $9.6 $- NM
- Other revenue adjustments 3 $(3.8) $(5.3) 28%
- Excise taxes $(16.0) $(10.5) (52%)
$63.3 $58.2 9%
Global medical net revenue
- Dry bud $9.0 $9.2 (2%)
- Oils and softgels $27.0 $24.3 11%
- Cannabis 2.0 products 2 $0.9 $- NM
- Excise taxes $(1.4) $(1.3) (8%)
$35.5 $32.2 10%
Cannabis net revenue $98.8 $90.4 9%
All other revenue $53.7 $33.4 61%
Net revenue $152.5 $123.8 23%
1 Excludes the impact of other revenue adjustments.
2 Cannabis 2.0 products include cannabis-infused chocolates, cannabis-infused beverages, and cannabis vape products (including power sources such as rechargeable and compact batteries, ready-to-go vape pens, and cartridges/vape pods)
3 Other revenue adjustments represent the Company's determination of returns and pricing adjustments, and relate to the Canadian recreational business-to-business channel.
International Cannabis
Strategic Businesses
The third quarter fiscal 2021 and third quarter fiscal 2020 financial results presented in this press release have been prepared in accordance with U.S. GAAP.
Webcast and Conference Call Information
The Company will host a conference call and audio webcast with David Klein, CEO and Mike Lee, CFO at 10:00 AM Eastern Time on February 9, 2021.
A live audio webcast will be available at:
A replay will be accessible by webcast until 11:59 PM ET on May 10, 2021 at:
Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net loss, adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; expected credit losses on financial assets and related charges; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs. The Adjusted EBITDA reconciliation is presented within this news release and explained in the Company's Quarterly Report on Form 10-Q to be filed with the SEC.
Free Cash Flow is a non- GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. This measure is calculated as net cash provided by (used in) operating activities less purchases of and deposits on property, plant and equipment. The Free Cash Flow reconciliation is presented within this news release and explained in the Company's Quarterly Report on Form 10-Q to be filed with the SEC.
Adjusted Gross Margin and Adjusted Gross Margin Percentage are non-GAAP measures used by management that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted Gross Margin is calculated as gross margin excluding restructuring costs recorded in cost of goods sold. Adjusted Gross Margin Percentage is calculated as Adjusted Gross Margin divided by net revenue. The Adjusted Gross Margin and Adjusted Gross Margin Percentage reconciliation is presented within this news release.
Vice President, Investor Relations & Competitive Intelligence
Director, Investor Relations
About Canopy Growth Corporation
Canopy Growth (TSX:WEED,NASDAQ:CGC ) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Forward-looking statements include, but are not limited to, statements with respect to:
Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.
The forward-looking statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) management's perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiii) our ability to continue to operate in light of the COVID-19 pandemic and the impact of the pandemic on demand for, and sales of, our products and our distribution channels; and (xiv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.
By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this press release and other reports we file with, or furnish to, the Securities and Exchange Commission (the "SEC") and other
regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, the risk that the COVID-19 pandemic may disrupt our operations and those of our suppliers and distribution channels and negatively impact the use of our products; consumer demand for cannabis and U.S. hemp products; that cost savings and any other synergies from the CBI Group Investments may not be fully realized or may take longer to realize than expected; future levels of revenues; our ability to manage disruptions in credit markets or changes to our credit rating; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); the potential effects of judicial or other proceedings on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; changes in regulatory requirements in relation to our business and products; and the factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2020 filed with the SEC on June 1, 2020. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.
Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
December 31, 2020 March 31, 2020
ASSETS
Current assets:
Cash and cash equivalents $824,960 $1,303,176
Short-term investments 768,564 673,323
Restricted short-term investments 11,426 21,539
Amounts receivable, net 93,673 90,155
Inventory 394,023 391,086
Prepaid expenses and other assets 78,979 85,094
Total current assets 2,171,625 2,564,373
Equity method investments 16,992 65,843
Other financial assets 682,595 249,253
Property, plant and equipment 1,148,338 1,524,803
Intangible assets 366,375 476,366
Goodwill 1,917,900 1,954,471
Other assets 5,357 22,636
Total assets $6,309,182 $6,857,745
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $86,463 $123,393
Other accrued expenses and liabilities 88,419 64,994
Current portion of long-term debt 13,031 16,393
Other liabilities 160,306 215,809
Total current liabilities 348,219 420,589
Long-term debt 619,165 449,022
Deferred income tax liabilities 23,251 47,113
Liability arising from Acreage Arrangement 450,000 250,000
Warrant derivative liability 415,946 322,491
Other liabilities 157,079 190,660
Total liabilities 2,013,660 1,679,875
Commitments and contingencies
Redeemable noncontrolling interest 111,100 69,750
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 373,803,786 shares and 350,112,927 shares, respectively 6,787,725 6,373,544
Additional paid-in capital 2,509,678 2,615,155
Accumulated other comprehensive income 27,407 220,899
Deficit (5,368,178) (4,323,236)
Total Canopy Growth Corporation shareholders' equity 3,956,632 4,886,362
Noncontrolling interests 227,790 221,758
Total shareholders' equity 4,184,422 5,108,120
Total liabilities and shareholders' equity $6,309,182 $6,857,745
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
Three months ended December 31, Nine months ended December 31,
2020 2019 2020 2019
Revenue $169,907 $135,546 $439,823 $324,558
Excise taxes 17,379 11,782 41,613 33,699
Net revenue 152,528 123,764 398,210 290,859
Cost of goods sold 127,943 85,556 341,050 230,718
Gross margin 24,585 38,208 57,160 60,141
Operating expenses:
Selling, general and administrative expenses 144,078 168,910 426,723 496,158
Share-based compensation 19,963 61,679 72,632 241,922
Expected credit losses on financial assets and related charges 13,735 - 108,480 -
Asset impairment and restructuring costs 400,422 - 459,579 -
Total operating expenses 578,198 230,589 1,067,414 738,080
Operating loss (553,613) (192,381) (1,010,254) (677,939)
Loss from equity method investments (671) (2,664) (40,851) (6,668)
Other income (expense), net (290,567) 57,963 (21,106) 600,624
Loss before income taxes (844,851) (137,082) (1,072,211) (83,983)
Income tax recovery 15,600 27,448 18,086 22,948
Net loss (829,251) (109,634) (1,054,125) (61,035)
Net income (loss) attributable to noncontrolling interests and redeemable noncontrolling interest 75,129 (18,280) (9,183) (42,730)
Net loss attributable to Canopy Growth Corporation $(904,380) $(91,354) $(1,044,942) $(18,305)
Basic and diluted loss per share $(2.43) $(0.26) $(2.83) $(0.05)
Basic and diluted weighted average common shares outstanding 372,908,767 348,530,622 369,418,037 346,877,660
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of Canadian dollars, unaudited)
Nine months ended December 31,
2020 2019
Cash flows from operating activities:
Net loss $(1,054,125) $(61,035)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment 54,625 49,582
Amortization of intangible assets 43,565 26,650
Share of loss on equity method investments 40,851 6,668
Share-based compensation 72,632 241,922
Asset impairment and restructuring costs 459,579 -
Expected credit losses on financial assets and related charges 108,480 -
Income tax recovery (18,086) (22,948)
Non-cash foreign currency (11,046) (3,945)
Interest paid (12,886) (13,738)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable (12,507) 13,749
Prepaid expenses and other assets (4,353) (6,214)
Inventory (28,520) (240,555)
Accounts payable and accrued liabilities (8,243) (11,559)
Other, including non-cash fair value adjustments 2,135 (540,573)
Net cash used in operating activities (367,899) (561,996)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment (137,977) (610,858)
Purchases of intangible assets (7,238) (13,724)
Proceeds on sale of property, plant and equipment 30,921 -
Proceeds on sale of intangible assets 18,337 -
(Purchases) redemption of short-term investments (83,612) 1,324,682
Sale of (investments in) equity method investments 7,000 (4,719)
Investments in other financial assets (34,236) (46,647)
Investment in Acreage Arrangement (49,849) (395,190)
Loan advanced to Acreage Hempco (66,995) -
Recovery of amounts related to construction financing 10,000 -
Payment of acquisition related liabilities (15,144) (29,837)
Net cash outflow on acquisition of noncontrolling interests (125) -
Net cash outflow on acquisition of subsidiaries - (505,156)
Net cash used in investing activities (328,918) (281,449)
Cash flows from financing activities:
Payment of share issue costs (670) (245)
Proceeds from issuance of shares by Canopy Rivers 92 1,062
Proceeds from exercise of stock options 37,999 39,149
Proceeds from exercise of warrants 244,990 446
Issuance of long-term debt - 10,268
Repayment of long-term debt (13,271) (122,036)
Net cash provided by (used in) financing activities 269,140 (71,356)
Effect of exchange rate changes on cash and cash equivalents (50,539) (4,365)
Net decrease in cash and cash equivalents (478,216) (919,166)
Cash and cash equivalents, beginning of period 1,303,176 2,480,830
Cash and cash equivalents, end of period $824,960 $1,561,664
Adjusted Gross Margin 1 Reconciliation (Non-GAAP Measure)
Three months ended December 31,
(in thousands of Canadian dollars, unaudited) 2020 2019
Net revenue $152,528 $123,764
Gross margin, as reported 24,585 38,208
Adjustments to gross margin:
Restructuring costs recorded in cost of goods sold 15,637 -
Adjusted gross margin 1 $40,222 $38,208
Adjusted gross margin percentage 1 26% 31%
1 Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Adjusted EBITDA 1 Reconciliation (Non-GAAP Measure)
Three months ended December 31,
(in thousands of Canadian dollars, unaudited) 2020 2019
Net loss $(829,251) $(109,634)
Income tax recovery (15,600) (27,448)
Other (income) expense, net 290,567 (57,963)
Loss on equity method investments 671 2,664
Share-based compensation 2 19,963 61,679
Acquisition-related costs 3,095 3,256
Depreciation and amortization 2 32,385 30,464
Asset impairment and restructuring costs 400,422 -
Expected credit losses on financial assets and related charges 13,735 -
Restructuring costs recorded in cost of goods sold 15,637 -
Adjusted EBITDA 1 $(68,376) $(96,982)
1 Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
2 From Condensed Interim Consolidated Statements of Cash Flows.
Free Cash Flow Reconciliation 1
Three months ended December 31,
(in thousands of Canadian dollars, unaudited) 2020 2019
Net cash used in operating activities $(87,604) $(189,911)
Purchases of and deposits on property, plant and equipment (47,782) (170,708)
Free cash flow 1 $(135,386) $(360,619)
1 Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
Last updated: Feb 9, 2021